Topical Finasteride: What It Is, How It Works, and What the Evidence Shows
Medically reviewed by [Reviewer Name, MD, Dermatology] | Last reviewed: August 2026 | Editorial policy | Sources
Off-label notice: There is no FDA-approved topical finasteride formulation in the United States as of 2026. Topical finasteride is compounded by specialty pharmacies and prescribed off-label. Any use requires a valid prescription from a licensed US physician.
Topical finasteride is a compounded formulation of finasteride designed to be applied directly to the scalp rather than taken orally. It is prescribed off-label for male androgenetic alopecia (AGA, male pattern hair loss) as an alternative to the FDA-approved oral finasteride 1 mg. The primary rationale is to achieve local DHT suppression in the scalp while minimizing systemic DHT reduction, thereby potentially reducing systemic side effects.
Why Topical? The Rationale
Oral finasteride 1 mg reduces serum (blood) DHT by approximately 70%. This systemic suppression is what drives the sexual side effects that a minority of men experience. The hypothesis behind topical finasteride is that applying the drug directly to the scalp can suppress scalp DHT, which is what treats hair loss, while resulting in far less systemic DHT reduction, theoretically lowering the risk of systemic hormonal side effects.
The pharmacological evidence supports this hypothesis to a meaningful degree: published Phase II/III trials of topical finasteride formulations show comparable scalp DHT suppression to oral finasteride, with smaller serum DHT reductions (34.5% vs. 55.6% for oral in the largest Phase III trial).
Clinical Evidence
Key Trials
| Study | Design | Key Findings |
|---|---|---|
| Mazzarella et al., 1997 | RCT; topical fin 0.005% vs. oral fin 1 mg; 16 weeks; n=20 | Both groups showed comparable hair growth; topical group had lower systemic DHT suppression |
| Caserini et al., 2016 | Two randomized pharmacodynamic studies; topical fin 0.25% solution; 1 week; n=50 | At 100 to 200 µL daily, scalp DHT fell 47% to 52% and serum DHT 24% to 26%; hair growth was not measured |
| Piraccini et al., 2022 | Phase III; topical fin 0.25% spray vs. placebo; 24 weeks; n=458 randomized | Statistically superior to placebo in target area hair count; low systemic DHT reduction; favorable safety profile |
The Piraccini et al. 2022 Phase III trial: the largest and most rigorous to date. Found that topical finasteride 0.25% spray produced statistically significant improvements in target area hair count vs. placebo at 24 weeks, with a serum DHT reduction of 34.5% (compared to 55.6% for oral finasteride 1 mg in the same trial). No FDA-approved version emerged from this program in the US.
Topical vs. Oral Finasteride: Comparison
| Oral Finasteride 1 mg | Topical Finasteride (compounded) | |
|---|---|---|
| FDA status (US) | Approved (Propecia 1 mg, 1997) | Not approved; off-label/compounded |
| Scalp DHT suppression | ~64% | 37% to 70% across doses (Caserini 2016) |
| Serum DHT suppression | ~70% | 34.5% in the Phase III trial (varies by formulation/dose) |
| Evidence base | 25+ year RCT and long-term data | Several Phase II/III trials; shorter follow-up |
| Hair efficacy vs. placebo | Well-established (Kaufman 1998) | Established in Phase III (Piraccini 2022) |
| Sexual side effect risk | ~1-2% above placebo | Lower in trials; larger studies needed |
| Prescription required | Yes | Yes (compounded; off-label) |
| Monthly cost | $15, $35 (generic) | $30, $70+ (compounded; varies by pharmacy) |
| Administration | Daily oral tablet | Daily scalp application (spray/solution) |
Who Might Consider Topical Finasteride?
Topical finasteride may be a reasonable discussion with your dermatologist if you:
- Are concerned about systemic hormonal side effects from oral finasteride
- Previously experienced sexual side effects on oral finasteride and want to try a lower-systemic-DHT alternative
- Prefer a locally-acting approach and are willing to accept the off-label, compounded status
Topical finasteride is not appropriate for women who are or may become pregnant. The teratogenicity risk applies to topical formulations as well, particularly if handled by or used by pregnant women.
Important Caveats
- No FDA-approved topical finasteride exists in the US. Any topical finasteride is compounded, which means formulation quality, concentration, and vehicle can vary between pharmacies.
- Compounded medications are not FDA-approved. They do not undergo the same safety and efficacy review as approved drugs.
- Long-term safety data are more limited than for oral finasteride, which has 25+ years of post-marketing data.
- Xyon topical finasteride (a proprietary LADD technology-based formulation) is one commercially available compounded option in the US and Canada. It is not FDA-approved for AGA.
Topical vs. oral finasteride: full side-by-side comparison | Topical finasteride side effects | Systemic absorption: how much DHT is suppressed?
Frequently Asked Questions
Is topical finasteride available at regular pharmacies?
No. Topical finasteride is not an FDA-approved product and is not stocked at standard retail pharmacies. It must be compounded by a licensed compounding pharmacy with a valid prescription from a US physician. Xyon topical finasteride is available through telehealth platforms and specialty compounding pharmacies.
Does topical finasteride work as well as oral?
Clinical trials suggest comparable efficacy at approved concentrations vs. oral finasteride in terms of hair count improvement, with the key advantage of significantly less systemic DHT suppression. However, the evidence base is smaller and longer-term comparative data (5+ years) do not yet exist for topical formulations. Oral finasteride 1 mg remains the FDA-approved standard first-line, with a stronger evidence base.
Can topical finasteride be used by women?
No. Topical finasteride is still absorbed systemically to some degree, and the teratogenicity risk (Pregnancy Category X) applies. Women who are or may become pregnant must not use or handle topical finasteride. For postmenopausal women considering topical finasteride for FPHL (female pattern hair loss), this is an off-label use that requires individualized physician assessment; current evidence is insufficient to make general recommendations.
About this page: Reviewed by [Reviewer Name, MD, Dermatology]. Trial data sourced from peer-reviewed publications. Last reviewed August 2026. Editorial policy. This page describes off-label, compounded use and has been reviewed by a pharma regulatory attorney for content compliance.
Sources
- Piraccini BM, et al. “Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia.” J Eur Acad Dermatol Venereol. 2022;36(2):286-294.
- Caserini M, et al. “Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia.” Int J Clin Pharmacol Ther. 2016;54(1):19-27.
- Mazzarella GF, et al. “Topical finasteride in the treatment of androgenic alopecia.” Arch Dermatol Res. 1997;289(Suppl 1):S43.